← Back to Search

Cardiovascular Care for Prostate Cancer

N/A
Recruiting
Led By Alicia Morgans, MD, MPH
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥18 years.
Be older than 18 years old
Must not have
Participants who have already been on ADT therapy for more than 12 weeks are ineligible due to their treatment cycle being incompatible with the quality improvement initiative's trial design. ADT therapy is defined as either a GnRH agonist or antagonist.
Participants receiving combination treatment with ADT and chemotherapy (docetaxel, cabazitaxel, carboplatin), radioligand therapy (radium-223, 177PSMA-lutetium-617), or treatment on a clinical trial are not eligible due to potential for more intensive symptom management that may be required for optimal support of their cancer-directed treatment.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 months (from 4 weeks after adt initiation to the week 24 on-treatment visit)
Awards & highlights

Summary

This trial is testing a program to assess and manage cardiovascular risk factors in prostate cancer patients starting hormone therapy. The goal is to create a standardized method for all patients at the Dana-Farber Cancer Institute

Who is the study for?
This trial is for individuals with prostate cancer who are beginning androgen deprivation therapy (ADT). It aims to help manage cardiovascular risks that may arise from their cancer treatment. Participants should be starting ADT soon or have started it recently.
What is being tested?
The study is testing a 'CV Care Program' designed to assess and manage heart health risks in patients undergoing ADT for prostate cancer. The goal is to see if this program can become a standard part of patient care at the Dana-Farber Cancer Institute.
What are the potential side effects?
Since the intervention involves assessment and management rather than medication, direct side effects are not expected as typically seen with drug trials. However, any changes made to manage CV risk could potentially have their own effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not been on ADT therapy for prostate cancer for more than 12 weeks.
Select...
I am not on ADT with chemotherapy, radioligand therapy, or any clinical trial treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 months (from 4 weeks after adt initiation to the week 24 on-treatment visit)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 months (from 4 weeks after adt initiation to the week 24 on-treatment visit) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Participant Retention Rate in CV CARE 2
Secondary study objectives
Proportion of Participants on Blood Pressure Medications in CV CARE
Proportion of Participants on Blood Pressure Medications in CV CARE 2
Proportion of Participants on Statin Medications in CV CARE
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: CV Care Program 2Experimental Treatment1 Intervention
Study procedures will be conducted as follows: * Standard of care androgen deprivation therapy. * 4 week standard-of-care follow up visit in clinic with CV care education module completion. * 12-week standard-of-care prostate cancer care visit with oncologist. * 24-week standard-of-care post-ADT visit in clinic with CV Care module completion, surveys, and exit interview with clinical team members. * Participant feedback from surveys, exit-interviews, and possibly focus groups will be collected.
Group II: CV Care ProgramExperimental Treatment1 Intervention
Study procedures will be conducted as follows: * Standard of care androgen deprivation therapy. * 4 week standard-of-care follow up visit in clinic with CV care education module completion. * 12-week standard-of-care prostate cancer care visit with oncologist. * 24-week standard-of-care post-ADT visit in clinic with CV Care module completion, surveys, and exit interview with clinical team members. * The CV Care program will be revised through participant feedback from assessments, surveys, focus groups, and exit-interviews. The revised CV Care Program will be used in the next cohort.

Find a Location

Who is running the clinical trial?

National Comprehensive Cancer NetworkNETWORK
118 Previous Clinical Trials
7,710 Total Patients Enrolled
6 Trials studying Prostate Cancer
254 Patients Enrolled for Prostate Cancer
Dana-Farber Cancer InstituteLead Sponsor
1,100 Previous Clinical Trials
352,917 Total Patients Enrolled
76 Trials studying Prostate Cancer
15,518 Patients Enrolled for Prostate Cancer
Alicia Morgans, MD, MPHPrincipal InvestigatorDana-Farber Cancer Institute
1 Previous Clinical Trials
57 Total Patients Enrolled
1 Trials studying Prostate Cancer
57 Patients Enrolled for Prostate Cancer
~120 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top